Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of a CpG/adjuvanted recombinant hepatitis B vaccine in adults using different immunization schedules
CTR20243962Phase 2Active
- Sponsor
- Grand Sevaxin
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant hepatitis B vaccine (hansenula polymorpha, CpG and aluminum adjuvant) in hepatitis B (HBV), sponsored by Grand Sevaxin. Started Oct 2024; status: active.
02
Drugs
recombinant hepatitis B vaccine (hansenula polymorpha, CpG and aluminum adjuvant)
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on CTR20243962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243962.